샘플 요청 목록

 카트 문의
시장보고서
상품코드
1536204

소아 간질 치료 시장

Pediatric Epilepsy Therapeutics
발행일: | 리서치사: 구분자 Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | 페이지 정보: 영문 184 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



가격
PDF & Excel (Single User License) help
PDF & Excel 보고서를 1명만 이용할 수 있는 라이선스입니다. 파일 내 텍스트의 복사 및 붙여넣기는 가능하지만, 표/그래프 등은 복사할 수 없습니다. 인쇄는 1회 가능하며, 인쇄물의 이용범위는 파일 이용범위와 동일합니다.
US $ 5,850 금액 안내 화살표 ￦ 8,715,000
PDF & Excel (Global License to Company and its Fully-owned Subsidiaries) help
PDF & Excel 보고서를 동일 기업 및 100% 자회사의 모든 분이 이용하실 수 있는 라이선스입니다. 인쇄는 1인당 1회 가능하며, 인쇄물의 이용범위는 파일 이용범위와 동일합니다.
US $ 17,550 금액 안내 화살표 ￦ 26,145,000
※ 부가세 별도
한글목차
영문목차
※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계의 소아 간질 치료 시장은 2030년까지 147억 달러에 도달

2023년에 117억 달러로 추정되는 세계의 소아 간질 치료 시장은 2023-2030년의 분석 기간에 CAGR 3.3%로 성장하며, 2030년에는 147억 달러에 달할 것으로 예측됩니다. 본 리포트에서 분석한 부문의 하나인 제3세대 의약품은 CAGR 4.1%를 기록하며, 분석 기간 종료시에는 70억 달러에 달할 것으로 예측됩니다. 제2세대 의약품 부문의 성장률은 분석 기간 중 CAGR 2.9%로 추정됩니다.

미국 시장은 32억 달러로 추정, 중국은 CAGR 6.5%로 성장 예측

미국의 소아 간질 치료 시장은 2023년에 32억 달러로 추정됩니다. 세계 2위의 경제대국인 중국은 분석 기간인 2023-2030년 CAGR 6.5%를 견인하며, 2030년까지 30억 달러의 시장 규모에 달할 것으로 예측됩니다. 기타 주목해야 할 지역별 시장으로는 일본과 캐나다가 있으며, 분석 기간 중 CAGR은 각각 1.0%와 2.5%로 예측됩니다. 유럽에서는 독일이 CAGR 1.8%로 성장할 것으로 예측됩니다.

세계의 소아 간질 치료 시장 - 주요 동향과 촉진요인 정리

소아 간질은 소아의 재발성 발작이 특징인 신경질환으로, 소아의 발달과 삶의 질에 큰 영향을 미치는 질환입니다. 소아 간질을 효과적으로 관리하기 위해서는 약리학적 치료, 생활습관 개선, 때로는 수술적 개입을 포함한 다학제적 접근이 필요합니다. 소아 간질 치료의 1차적인 목표는 부작용을 최소화하면서 발작을 조절하고 정상적인 인지 및 신체 발달을 가능하게 하는 것입니다. 항간질약(AED)은 치료의 핵심이며, 발프로산, 레베티라세탐, 라모트리진 등이 자주 처방됩니다. 이러한 약물은 신경 활동을 안정시키고 발작의 원인이 되는 비정상적인 전기적 방전을 방지하여 효과를 발휘합니다. 치료 요법은 간질의 유형, 아이의 나이, 동반 질환 등을 고려해 개인에 맞게 조정되는 경우가 많습니다.

최근 소아 뇌전증 치료의 동향는 기존 치료제의 효과와 안전성을 향상시키는 동시에 새로운 치료법을 개발하는 데 중점을 두고 있습니다. 서방형 제제나 새로운 약물전달 시스템과 같은 기술 혁신은 투여 횟수를 줄이고 부작용을 최소화하여 환자의 순응도를 높이는 것을 목표로 하고 있습니다. 또한 간질의 유전적 기반에 대한 연구를 통해 간질과 관련된 특정 유전자 변이에 대응하는 표적 치료제가 개발되고 있습니다. 이러한 정밀의학 접근법은 치료 결과를 개선할 뿐만 아니라 적절한 약물을 찾기 위해 종종 수반되는 시행착오의 기간을 단축할 수 있습니다. 케토제닉 다이어트나 신경자극기와 같은 비약리학적 치료법도 보완적인 치료법으로 각광받고 있으며, 기존의 약물 치료로 불응하는 난치성 간질 환자를 관리할 수 있는 새로운 수단을 제공합니다.

소아 간질 치료 시장의 성장은 기술 발전, 간질에 대한 인식과 진단의 향상, 간질 유병률 증가 등 여러 요인에 기인합니다. 웨어러블 발작 감지 장비 및 첨단 신경 영상 기술 개발과 같은 기술 혁신은 보다 빠르고 정확한 진단을 가능하게 하여 효과적인 치료에 대한 수요를 증가시키고 있습니다. 또한 간질의 유전적 기반에 대한 이해가 깊어지면서 표적 치료의 새로운 가능성을 열어주는 것도 시장을 촉진하고 있습니다. 또한 신흥 시장에서의 의료 서비스 개선과 의료 접근성 향상으로 인해 소아 간질 치료제 시장 규모가 확대되고 있습니다. 희귀질환 치료제 및 소아 전용 의약품에 대한 규제 당국의 지원은 새로운 치료제의 개발 및 승인을 더욱 가속화하고 있습니다. 이러한 추세에 따라 소아 간질 치료제 시장은 지속적으로 성장하여 소아 간질 환아 및 가족에게 더 나은 치료 옵션과 더 나은 결과를 제공할 것으로 기대됩니다.

조사 대상 기업의 예(총 86건)

  • Azurity Pharmaceuticals, Inc.
  • Biogen, Inc.
  • Bio-Pharm Solutions Company Limited
  • Eisai Co., Ltd.
  • EpyGenix Therapeutics
  • GSK Plc
  • Jazz Pharmaceuticals Plc
  • Marinus Pharmaceuticals, Inc.
  • Neurelis, Inc.
  • Neurocrine Biosciences, Inc.
  • Praxis Precision Medicines
  • Regeneron Pharmaceuticals, Inc.
  • Sanofi SA
  • Takeda Pharmaceutical Co., Ltd.
  • UCB SA

목차

제1장 조사 방법

제2장 개요

  • 시장 개요
  • 주요 기업
  • 시장 동향과 촉진요인
  • 세계 시장의 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 스페인
  • 러시아
  • 기타 유럽
  • 아시아태평양
  • 호주
  • 인도
  • 한국
  • 기타 아시아태평양
  • 라틴아메리카
  • 아르헨티나
  • 브라질
  • 멕시코
  • 기타 라틴아메리카
  • 중동
  • 이란
  • 이스라엘
  • 사우디아라비아
  • 아랍에미리트
  • 기타 중동
  • 아프리카

제4장 경쟁

KSA 24.08.27

Global Pediatric Epilepsy Therapeutics Market to Reach US$14.7 Billion by 2030

The global market for Pediatric Epilepsy Therapeutics estimated at US$11.7 Billion in the year 2023, is expected to reach US$14.7 Billion by 2030, growing at a CAGR of 3.3% over the analysis period 2023-2030. Third Generation Drugs, one of the segments analyzed in the report, is expected to record a 4.1% CAGR and reach US$7.0 Billion by the end of the analysis period. Growth in the Second Generation Drugs segment is estimated at 2.9% CAGR over the analysis period.

The U.S. Market is Estimated at US$3.2 Billion While China is Forecast to Grow at 6.5% CAGR

The Pediatric Epilepsy Therapeutics market in the U.S. is estimated at US$3.2 Billion in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$3.0 Billion by the year 2030 trailing a CAGR of 6.5% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.0% and 2.5% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 1.8% CAGR.

Global Pediatric Epilepsy Therapeutics Market - Key Trends and Drivers Summarized

Pediatric epilepsy is a neurological disorder characterized by recurrent seizures in children, significantly impacting their development and quality of life. Effective management of pediatric epilepsy involves a multidisciplinary approach, including pharmacological treatments, lifestyle modifications, and sometimes surgical interventions. The primary goal of pediatric epilepsy therapeutics is to achieve seizure control with minimal side effects, thereby allowing normal cognitive and physical development. Antiepileptic drugs (AEDs) are the cornerstone of treatment, with options such as valproate, levetiracetam, and lamotrigine being commonly prescribed. These medications work by stabilizing neural activity and preventing the abnormal electrical discharges that cause seizures. Treatment regimens are often tailored to the individual, taking into account the type of epilepsy, the child’s age, and any co-existing conditions.

Recent advancements in pediatric epilepsy therapeutics have focused on improving the efficacy and safety profile of existing medications while also developing novel treatment options. Innovations such as extended-release formulations and new drug delivery systems aim to enhance patient compliance by reducing the frequency of dosing and minimizing side effects. Additionally, research into the genetic underpinnings of epilepsy has led to the development of targeted therapies that address specific genetic mutations associated with the disorder. This precision medicine approach not only improves treatment outcomes but also reduces the trial-and-error period often associated with finding the right medication. Non-pharmacological treatments, such as ketogenic diets and neurostimulation devices, are also gaining traction as complementary therapies, providing additional avenues for managing refractory epilepsy cases where traditional medications fall short.

The growth in the pediatric epilepsy therapeutics market is driven by several factors, including technological advancements, increased awareness and diagnosis of epilepsy, and the rising prevalence of the disorder. Technological innovations, such as the development of wearable seizure detection devices and advanced neuroimaging techniques, are enabling earlier and more accurate diagnosis, which in turn drives demand for effective treatments. The growing understanding of epilepsy’s genetic basis is also propelling the market, as it opens up new possibilities for targeted therapies. Moreover, the increasing availability of healthcare services and improved access to medical care in emerging markets are expanding the addressable market for pediatric epilepsy treatments. Regulatory support for orphan drugs and pediatric-specific formulations is further accelerating the development and approval of new therapies. As these trends continue, the pediatric epilepsy therapeutics market is poised for sustained growth, offering improved treatment options and better outcomes for affected children and their families.

Select Competitors (Total 86 Featured) -

  • Azurity Pharmaceuticals, Inc.
  • Biogen, Inc.
  • Bio-Pharm Solutions Company Limited
  • Eisai Co., Ltd.
  • EpyGenix Therapeutics
  • GSK Plc
  • Jazz Pharmaceuticals Plc
  • Marinus Pharmaceuticals, Inc.
  • Neurelis, Inc.
  • Neurocrine Biosciences, Inc.
  • Praxis Precision Medicines
  • Regeneron Pharmaceuticals, Inc.
  • Sanofi SA
  • Takeda Pharmaceutical Co., Ltd.
  • UCB SA

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Global Economic Update
    • Pediatric Epilepsy Therapeutics - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Technological Innovations Propel Growth in Pediatric Epilepsy Therapeutics Market
    • Rising Prevalence of Pediatric Epilepsy Expands Addressable Market Opportunity
    • Increased Awareness and Early Diagnosis Drives Demand for Effective Treatments
    • Advances in Genetic Research Strengthen Business Case for Targeted Therapies
    • Development of Wearable Seizure Detection Devices Spurs Market Growth
    • Growing Adoption of Precision Medicine Approaches Drives Adoption of New Therapies
    • Non-Pharmacological Treatments Gain Traction as Complementary Therapies
    • Improved Access to Healthcare Services in Emerging Markets Expands Market Reach
    • Increasing Investment in Pediatric Neurology Research Generates New Opportunities
    • Enhanced Neuroimaging Techniques Accelerate Accurate Diagnosis and Treatment Planning
    • Rising Healthcare Expenditure Supports Sustained Market Growth
    • Evolution of Personalized Treatment Plans Improves Patient Outcomes
    • Increased Focus on Minimizing Side Effects Drives Development of Safer Medications
    • Expansion of Telemedicine Services Creates New Opportunities for Pediatric Epilepsy Care
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Pediatric Epilepsy Therapeutics Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Pediatric Epilepsy Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Pediatric Epilepsy Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 4: World 16-Year Perspective for Pediatric Epilepsy Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Third Generation by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Third Generation by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 7: World 16-Year Perspective for Third Generation by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Second Generation by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Second Generation by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 10: World 16-Year Perspective for Second Generation by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for First Generation by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 12: World Historic Review for First Generation by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 13: World 16-Year Perspective for First Generation by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Pediatric Epilepsy Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 14: USA Recent Past, Current & Future Analysis for Pediatric Epilepsy Therapeutics by Product Type - Third Generation, Second Generation and First Generation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 15: USA Historic Review for Pediatric Epilepsy Therapeutics by Product Type - Third Generation, Second Generation and First Generation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 16: USA 16-Year Perspective for Pediatric Epilepsy Therapeutics by Product Type - Percentage Breakdown of Value Sales for Third Generation, Second Generation and First Generation for the Years 2014, 2024 & 2030
  • CANADA
    • TABLE 17: Canada Recent Past, Current & Future Analysis for Pediatric Epilepsy Therapeutics by Product Type - Third Generation, Second Generation and First Generation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 18: Canada Historic Review for Pediatric Epilepsy Therapeutics by Product Type - Third Generation, Second Generation and First Generation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 19: Canada 16-Year Perspective for Pediatric Epilepsy Therapeutics by Product Type - Percentage Breakdown of Value Sales for Third Generation, Second Generation and First Generation for the Years 2014, 2024 & 2030
  • JAPAN
    • Pediatric Epilepsy Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 20: Japan Recent Past, Current & Future Analysis for Pediatric Epilepsy Therapeutics by Product Type - Third Generation, Second Generation and First Generation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 21: Japan Historic Review for Pediatric Epilepsy Therapeutics by Product Type - Third Generation, Second Generation and First Generation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 22: Japan 16-Year Perspective for Pediatric Epilepsy Therapeutics by Product Type - Percentage Breakdown of Value Sales for Third Generation, Second Generation and First Generation for the Years 2014, 2024 & 2030
  • CHINA
    • Pediatric Epilepsy Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 23: China Recent Past, Current & Future Analysis for Pediatric Epilepsy Therapeutics by Product Type - Third Generation, Second Generation and First Generation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 24: China Historic Review for Pediatric Epilepsy Therapeutics by Product Type - Third Generation, Second Generation and First Generation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 25: China 16-Year Perspective for Pediatric Epilepsy Therapeutics by Product Type - Percentage Breakdown of Value Sales for Third Generation, Second Generation and First Generation for the Years 2014, 2024 & 2030
  • EUROPE
    • Pediatric Epilepsy Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 26: Europe Recent Past, Current & Future Analysis for Pediatric Epilepsy Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 27: Europe Historic Review for Pediatric Epilepsy Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 28: Europe 16-Year Perspective for Pediatric Epilepsy Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
    • TABLE 29: Europe Recent Past, Current & Future Analysis for Pediatric Epilepsy Therapeutics by Product Type - Third Generation, Second Generation and First Generation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 30: Europe Historic Review for Pediatric Epilepsy Therapeutics by Product Type - Third Generation, Second Generation and First Generation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 31: Europe 16-Year Perspective for Pediatric Epilepsy Therapeutics by Product Type - Percentage Breakdown of Value Sales for Third Generation, Second Generation and First Generation for the Years 2014, 2024 & 2030
  • FRANCE
    • Pediatric Epilepsy Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 32: France Recent Past, Current & Future Analysis for Pediatric Epilepsy Therapeutics by Product Type - Third Generation, Second Generation and First Generation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 33: France Historic Review for Pediatric Epilepsy Therapeutics by Product Type - Third Generation, Second Generation and First Generation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 34: France 16-Year Perspective for Pediatric Epilepsy Therapeutics by Product Type - Percentage Breakdown of Value Sales for Third Generation, Second Generation and First Generation for the Years 2014, 2024 & 2030
  • GERMANY
    • Pediatric Epilepsy Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 35: Germany Recent Past, Current & Future Analysis for Pediatric Epilepsy Therapeutics by Product Type - Third Generation, Second Generation and First Generation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 36: Germany Historic Review for Pediatric Epilepsy Therapeutics by Product Type - Third Generation, Second Generation and First Generation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 37: Germany 16-Year Perspective for Pediatric Epilepsy Therapeutics by Product Type - Percentage Breakdown of Value Sales for Third Generation, Second Generation and First Generation for the Years 2014, 2024 & 2030
  • ITALY
    • TABLE 38: Italy Recent Past, Current & Future Analysis for Pediatric Epilepsy Therapeutics by Product Type - Third Generation, Second Generation and First Generation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 39: Italy Historic Review for Pediatric Epilepsy Therapeutics by Product Type - Third Generation, Second Generation and First Generation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 40: Italy 16-Year Perspective for Pediatric Epilepsy Therapeutics by Product Type - Percentage Breakdown of Value Sales for Third Generation, Second Generation and First Generation for the Years 2014, 2024 & 2030
  • UNITED KINGDOM
    • Pediatric Epilepsy Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 41: UK Recent Past, Current & Future Analysis for Pediatric Epilepsy Therapeutics by Product Type - Third Generation, Second Generation and First Generation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 42: UK Historic Review for Pediatric Epilepsy Therapeutics by Product Type - Third Generation, Second Generation and First Generation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 43: UK 16-Year Perspective for Pediatric Epilepsy Therapeutics by Product Type - Percentage Breakdown of Value Sales for Third Generation, Second Generation and First Generation for the Years 2014, 2024 & 2030
  • SPAIN
    • TABLE 44: Spain Recent Past, Current & Future Analysis for Pediatric Epilepsy Therapeutics by Product Type - Third Generation, Second Generation and First Generation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 45: Spain Historic Review for Pediatric Epilepsy Therapeutics by Product Type - Third Generation, Second Generation and First Generation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 46: Spain 16-Year Perspective for Pediatric Epilepsy Therapeutics by Product Type - Percentage Breakdown of Value Sales for Third Generation, Second Generation and First Generation for the Years 2014, 2024 & 2030
  • RUSSIA
    • TABLE 47: Russia Recent Past, Current & Future Analysis for Pediatric Epilepsy Therapeutics by Product Type - Third Generation, Second Generation and First Generation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 48: Russia Historic Review for Pediatric Epilepsy Therapeutics by Product Type - Third Generation, Second Generation and First Generation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 49: Russia 16-Year Perspective for Pediatric Epilepsy Therapeutics by Product Type - Percentage Breakdown of Value Sales for Third Generation, Second Generation and First Generation for the Years 2014, 2024 & 2030
  • REST OF EUROPE
    • TABLE 50: Rest of Europe Recent Past, Current & Future Analysis for Pediatric Epilepsy Therapeutics by Product Type - Third Generation, Second Generation and First Generation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 51: Rest of Europe Historic Review for Pediatric Epilepsy Therapeutics by Product Type - Third Generation, Second Generation and First Generation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 52: Rest of Europe 16-Year Perspective for Pediatric Epilepsy Therapeutics by Product Type - Percentage Breakdown of Value Sales for Third Generation, Second Generation and First Generation for the Years 2014, 2024 & 2030
  • ASIA-PACIFIC
    • Pediatric Epilepsy Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 53: Asia-Pacific Recent Past, Current & Future Analysis for Pediatric Epilepsy Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 54: Asia-Pacific Historic Review for Pediatric Epilepsy Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 55: Asia-Pacific 16-Year Perspective for Pediatric Epilepsy Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
    • TABLE 56: Asia-Pacific Recent Past, Current & Future Analysis for Pediatric Epilepsy Therapeutics by Product Type - Third Generation, Second Generation and First Generation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 57: Asia-Pacific Historic Review for Pediatric Epilepsy Therapeutics by Product Type - Third Generation, Second Generation and First Generation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 58: Asia-Pacific 16-Year Perspective for Pediatric Epilepsy Therapeutics by Product Type - Percentage Breakdown of Value Sales for Third Generation, Second Generation and First Generation for the Years 2014, 2024 & 2030
  • AUSTRALIA
    • Pediatric Epilepsy Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
    • TABLE 59: Australia Recent Past, Current & Future Analysis for Pediatric Epilepsy Therapeutics by Product Type - Third Generation, Second Generation and First Generation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 60: Australia Historic Review for Pediatric Epilepsy Therapeutics by Product Type - Third Generation, Second Generation and First Generation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 61: Australia 16-Year Perspective for Pediatric Epilepsy Therapeutics by Product Type - Percentage Breakdown of Value Sales for Third Generation, Second Generation and First Generation for the Years 2014, 2024 & 2030
  • INDIA
    • Pediatric Epilepsy Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
    • TABLE 62: India Recent Past, Current & Future Analysis for Pediatric Epilepsy Therapeutics by Product Type - Third Generation, Second Generation and First Generation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 63: India Historic Review for Pediatric Epilepsy Therapeutics by Product Type - Third Generation, Second Generation and First Generation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 64: India 16-Year Perspective for Pediatric Epilepsy Therapeutics by Product Type - Percentage Breakdown of Value Sales for Third Generation, Second Generation and First Generation for the Years 2014, 2024 & 2030
  • SOUTH KOREA
    • TABLE 65: South Korea Recent Past, Current & Future Analysis for Pediatric Epilepsy Therapeutics by Product Type - Third Generation, Second Generation and First Generation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 66: South Korea Historic Review for Pediatric Epilepsy Therapeutics by Product Type - Third Generation, Second Generation and First Generation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 67: South Korea 16-Year Perspective for Pediatric Epilepsy Therapeutics by Product Type - Percentage Breakdown of Value Sales for Third Generation, Second Generation and First Generation for the Years 2014, 2024 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 68: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Pediatric Epilepsy Therapeutics by Product Type - Third Generation, Second Generation and First Generation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 69: Rest of Asia-Pacific Historic Review for Pediatric Epilepsy Therapeutics by Product Type - Third Generation, Second Generation and First Generation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 70: Rest of Asia-Pacific 16-Year Perspective for Pediatric Epilepsy Therapeutics by Product Type - Percentage Breakdown of Value Sales for Third Generation, Second Generation and First Generation for the Years 2014, 2024 & 2030
  • LATIN AMERICA
    • Pediatric Epilepsy Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
    • TABLE 71: Latin America Recent Past, Current & Future Analysis for Pediatric Epilepsy Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 72: Latin America Historic Review for Pediatric Epilepsy Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 73: Latin America 16-Year Perspective for Pediatric Epilepsy Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030
    • TABLE 74: Latin America Recent Past, Current & Future Analysis for Pediatric Epilepsy Therapeutics by Product Type - Third Generation, Second Generation and First Generation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 75: Latin America Historic Review for Pediatric Epilepsy Therapeutics by Product Type - Third Generation, Second Generation and First Generation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 76: Latin America 16-Year Perspective for Pediatric Epilepsy Therapeutics by Product Type - Percentage Breakdown of Value Sales for Third Generation, Second Generation and First Generation for the Years 2014, 2024 & 2030
  • ARGENTINA
    • TABLE 77: Argentina Recent Past, Current & Future Analysis for Pediatric Epilepsy Therapeutics by Product Type - Third Generation, Second Generation and First Generation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 78: Argentina Historic Review for Pediatric Epilepsy Therapeutics by Product Type - Third Generation, Second Generation and First Generation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 79: Argentina 16-Year Perspective for Pediatric Epilepsy Therapeutics by Product Type - Percentage Breakdown of Value Sales for Third Generation, Second Generation and First Generation for the Years 2014, 2024 & 2030
  • BRAZIL
    • TABLE 80: Brazil Recent Past, Current & Future Analysis for Pediatric Epilepsy Therapeutics by Product Type - Third Generation, Second Generation and First Generation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 81: Brazil Historic Review for Pediatric Epilepsy Therapeutics by Product Type - Third Generation, Second Generation and First Generation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 82: Brazil 16-Year Perspective for Pediatric Epilepsy Therapeutics by Product Type - Percentage Breakdown of Value Sales for Third Generation, Second Generation and First Generation for the Years 2014, 2024 & 2030
  • MEXICO
    • TABLE 83: Mexico Recent Past, Current & Future Analysis for Pediatric Epilepsy Therapeutics by Product Type - Third Generation, Second Generation and First Generation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 84: Mexico Historic Review for Pediatric Epilepsy Therapeutics by Product Type - Third Generation, Second Generation and First Generation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 85: Mexico 16-Year Perspective for Pediatric Epilepsy Therapeutics by Product Type - Percentage Breakdown of Value Sales for Third Generation, Second Generation and First Generation for the Years 2014, 2024 & 2030
  • REST OF LATIN AMERICA
    • TABLE 86: Rest of Latin America Recent Past, Current & Future Analysis for Pediatric Epilepsy Therapeutics by Product Type - Third Generation, Second Generation and First Generation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 87: Rest of Latin America Historic Review for Pediatric Epilepsy Therapeutics by Product Type - Third Generation, Second Generation and First Generation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 88: Rest of Latin America 16-Year Perspective for Pediatric Epilepsy Therapeutics by Product Type - Percentage Breakdown of Value Sales for Third Generation, Second Generation and First Generation for the Years 2014, 2024 & 2030
  • MIDDLE EAST
    • Pediatric Epilepsy Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
    • TABLE 89: Middle East Recent Past, Current & Future Analysis for Pediatric Epilepsy Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 90: Middle East Historic Review for Pediatric Epilepsy Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 91: Middle East 16-Year Perspective for Pediatric Epilepsy Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030
    • TABLE 92: Middle East Recent Past, Current & Future Analysis for Pediatric Epilepsy Therapeutics by Product Type - Third Generation, Second Generation and First Generation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 93: Middle East Historic Review for Pediatric Epilepsy Therapeutics by Product Type - Third Generation, Second Generation and First Generation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 94: Middle East 16-Year Perspective for Pediatric Epilepsy Therapeutics by Product Type - Percentage Breakdown of Value Sales for Third Generation, Second Generation and First Generation for the Years 2014, 2024 & 2030
  • IRAN
    • TABLE 95: Iran Recent Past, Current & Future Analysis for Pediatric Epilepsy Therapeutics by Product Type - Third Generation, Second Generation and First Generation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 96: Iran Historic Review for Pediatric Epilepsy Therapeutics by Product Type - Third Generation, Second Generation and First Generation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 97: Iran 16-Year Perspective for Pediatric Epilepsy Therapeutics by Product Type - Percentage Breakdown of Value Sales for Third Generation, Second Generation and First Generation for the Years 2014, 2024 & 2030
  • ISRAEL
    • TABLE 98: Israel Recent Past, Current & Future Analysis for Pediatric Epilepsy Therapeutics by Product Type - Third Generation, Second Generation and First Generation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 99: Israel Historic Review for Pediatric Epilepsy Therapeutics by Product Type - Third Generation, Second Generation and First Generation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 100: Israel 16-Year Perspective for Pediatric Epilepsy Therapeutics by Product Type - Percentage Breakdown of Value Sales for Third Generation, Second Generation and First Generation for the Years 2014, 2024 & 2030
  • SAUDI ARABIA
    • TABLE 101: Saudi Arabia Recent Past, Current & Future Analysis for Pediatric Epilepsy Therapeutics by Product Type - Third Generation, Second Generation and First Generation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 102: Saudi Arabia Historic Review for Pediatric Epilepsy Therapeutics by Product Type - Third Generation, Second Generation and First Generation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 103: Saudi Arabia 16-Year Perspective for Pediatric Epilepsy Therapeutics by Product Type - Percentage Breakdown of Value Sales for Third Generation, Second Generation and First Generation for the Years 2014, 2024 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 104: UAE Recent Past, Current & Future Analysis for Pediatric Epilepsy Therapeutics by Product Type - Third Generation, Second Generation and First Generation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 105: UAE Historic Review for Pediatric Epilepsy Therapeutics by Product Type - Third Generation, Second Generation and First Generation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 106: UAE 16-Year Perspective for Pediatric Epilepsy Therapeutics by Product Type - Percentage Breakdown of Value Sales for Third Generation, Second Generation and First Generation for the Years 2014, 2024 & 2030
  • REST OF MIDDLE EAST
    • TABLE 107: Rest of Middle East Recent Past, Current & Future Analysis for Pediatric Epilepsy Therapeutics by Product Type - Third Generation, Second Generation and First Generation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 108: Rest of Middle East Historic Review for Pediatric Epilepsy Therapeutics by Product Type - Third Generation, Second Generation and First Generation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 109: Rest of Middle East 16-Year Perspective for Pediatric Epilepsy Therapeutics by Product Type - Percentage Breakdown of Value Sales for Third Generation, Second Generation and First Generation for the Years 2014, 2024 & 2030
  • AFRICA
    • Pediatric Epilepsy Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
    • TABLE 110: Africa Recent Past, Current & Future Analysis for Pediatric Epilepsy Therapeutics by Product Type - Third Generation, Second Generation and First Generation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 111: Africa Historic Review for Pediatric Epilepsy Therapeutics by Product Type - Third Generation, Second Generation and First Generation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 112: Africa 16-Year Perspective for Pediatric Epilepsy Therapeutics by Product Type - Percentage Breakdown of Value Sales for Third Generation, Second Generation and First Generation for the Years 2014, 2024 & 2030

IV. COMPETITION

×

원하시는 정보를 찾아 드릴까요?

보안문자 새로고침
샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제
문의
원하시는 정보를
찾아 드릴까요?
문의주시면 필요한 정보를
신속하게 찾아드릴게요.
02-2025-2992
email
문의하기